Physician profile
Young B Lee
NPI 1932133519
$2,670.00
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $629 · 2021: $854 · 2022: $539.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.30 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $470.80 | 2019-2021 | |
| Nevro Corp. | $346.33 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $249.26 | 2022 | |
| Providence Medical Technology, INC. | $149.82 | 2022 | |
| Vanda Pharmaceuticals INC. | $116.80 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.33 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $92.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $88.09 | 2019-2021 | |
| Lundbeck LLC | $65.82 | 2020-2021 | |
| Alkermes, INC. | $59.30 | 2020-2021 | |
| Neos Therapeutics, LP | $55.26 | 2020 | |
| Eisai INC. | $51.90 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.64 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42.31 | 2019-2020 | |
| Bausch Health US, LLC | $41.45 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $28.02 | 2020-2021 | |
| Neuronetics, INC. | $15.77 | 2019 | |
| Mdd US Operations, LLC | $14.66 | 2019 | |
| Amgen INC. | $14.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.10 | 2020 | |
| Adlon Therapeutics L.P. | $13.86 | 2020 | |
| Shire North American Group INC | $12.29 | 2019 | |
| Noven Therapeutics, LLC | $11.56 | 2021 | |
| Almatica Pharma LLC | $11.33 | 2021 | |
| Owp Pharmaceuticals, INC. | $11.29 | 2019 | |
| Validus Pharmaceuticals LLC | $8.28 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.